4,6-diamino-2-butylsulfanylnicotinonitrile

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: 4,6-diamino-2-butylsulfanylnicotinonitrile
• 英文别名: 4,6-Diamino-2-butylsulfanylpyridine-3-carbonitrile
• 化学式: C₁₀H₁₄N₄S
• 分子量: 222.314
• InChiKey: YYWWYNDDZMLTJB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  114
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4,6-diamino-2-butylsulfanylnicotinonitrile 、 乙酰氯 在 吡啶 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 以100%的产率得到N-(4-Amino-6-butylsulfanyl-5-cyano-pyridin-2-yl)-acetamide
  参考文献：
  名称：

  Aminopyridine-Based c-Jun N-Terminal Kinase Inhibitors with Cellular Activity and Minimal Cross-Kinase Activity

  摘要：

  The c-Jun N-terminal kinases (JNK-1, -2, and -3) are members of the mitogen activated protein (MAP) kinase family of enzymes. They are activated in response to certain cytokines, as well as by cellular stresses including chemotoxins, peroxides, and irradiation. They have been implicated in the pathology of a variety of different diseases with an inflammatory component including asthma, stroke, Alzheimer's disease, and type 2 diabetes mellitus. In this work, high-throughput screening identified a JNK inhibitor with an excellent kinase selectivity profile. Using X-ray crystallography and biochemical screening to guide our lead optimization, we prepared compounds with inhibitory potencies in the low-double-digit nanomolar range, activity in whole cells, and pharmacokinetics suitable for in vivo use. The new compounds were over 1,000-fold selective for JNK-1 and -2 over other MAP kinases including ERK2, p38alpha, and p38delta and showed little inhibitory activity against a panel of 74 kinases.

  DOI：

  10.1021/jm060199b
• 作为产物：
  描述：

  丁硫醇 、 4,6-二氨基-2-溴烟腈 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 0.5h， 以52%的产率得到4,6-diamino-2-butylsulfanylnicotinonitrile
  参考文献：
  名称：

  Aminopyridine-Based c-Jun N-Terminal Kinase Inhibitors with Cellular Activity and Minimal Cross-Kinase Activity

  摘要：

  The c-Jun N-terminal kinases (JNK-1, -2, and -3) are members of the mitogen activated protein (MAP) kinase family of enzymes. They are activated in response to certain cytokines, as well as by cellular stresses including chemotoxins, peroxides, and irradiation. They have been implicated in the pathology of a variety of different diseases with an inflammatory component including asthma, stroke, Alzheimer's disease, and type 2 diabetes mellitus. In this work, high-throughput screening identified a JNK inhibitor with an excellent kinase selectivity profile. Using X-ray crystallography and biochemical screening to guide our lead optimization, we prepared compounds with inhibitory potencies in the low-double-digit nanomolar range, activity in whole cells, and pharmacokinetics suitable for in vivo use. The new compounds were over 1,000-fold selective for JNK-1 and -2 over other MAP kinases including ERK2, p38alpha, and p38delta and showed little inhibitory activity against a panel of 74 kinases.

  DOI：

  10.1021/jm060199b

文献信息

• Aminopyridine-Based c-Jun N-Terminal Kinase Inhibitors with Cellular Activity and Minimal Cross-Kinase Activity
  作者：Bruce G. Szczepankiewicz、Christi Kosogof、Lissa T. J. Nelson、Gang Liu、Bo Liu、Hongyu Zhao、Michael D. Serby、Zhili Xin、Mei Liu、Rebecca J. Gum、Deanna L. Haasch、Sanyi Wang、Jill E. Clampit、Eric F. Johnson、Thomas H. Lubben、Michael A. Stashko、Edward T. Olejniczak、Chaohong Sun、Sarah A. Dorwin、Kristi Haskins、Cele Abad-Zapatero、Elizabeth H. Fry、Charles W. Hutchins、Hing L. Sham、Cristina M. Rondinone、James M. Trevillyan

  DOI：10.1021/jm060199b

  日期：2006.6.1

  The c-Jun N-terminal kinases (JNK-1, -2, and -3) are members of the mitogen activated protein (MAP) kinase family of enzymes. They are activated in response to certain cytokines, as well as by cellular stresses including chemotoxins, peroxides, and irradiation. They have been implicated in the pathology of a variety of different diseases with an inflammatory component including asthma, stroke, Alzheimer's disease, and type 2 diabetes mellitus. In this work, high-throughput screening identified a JNK inhibitor with an excellent kinase selectivity profile. Using X-ray crystallography and biochemical screening to guide our lead optimization, we prepared compounds with inhibitory potencies in the low-double-digit nanomolar range, activity in whole cells, and pharmacokinetics suitable for in vivo use. The new compounds were over 1,000-fold selective for JNK-1 and -2 over other MAP kinases including ERK2, p38alpha, and p38delta and showed little inhibitory activity against a panel of 74 kinases.